On 20 August 2020, three prominent religious leaders in Australia wrote to the Prime Minister to express concerns about the ethical dilemma associated with calls to make vaccination for COVID-19 mandatory.
This followed the announcement that the Australian Government had signed a letter of intent to secure supply of the AstraZeneca/Oxford University COVID-19 vaccine should the current clinical trials prove successful.
The central concern is that the production of the vaccine uses a cell line HEK-293 that is cultured from electively aborted human foetus and that the Australian Government should support supply of an alternative uncontroversial vaccine if mandatory vaccination for COVID-19 is to be introduced.
Read more
Given the implications for potential take-up of a vaccine, its important to unpack this concern as well as the general ethical concerns from using human cell lines.
Manufacturing of the Oxford vaccine involves human kidney cells. These cells are used as factories to make the component of the vaccine that carries genes from the SARS-CoV-2 virus with the aim of triggering an immune response to protect the recipient when injected.
The type of cells used are descendants of cells first obtained in the early 1970s, from a foetus which was probably electively aborted (although records have now been lost).
These cells were cultured in the laboratory to produce what is called a cell line, a population of cells that have adapted to grow continuously in culture while retaining uniform characteristics.
Once created, cell lines are usually shared with researchers in different laboratories and referred to by a simple reference code. In the case of this foetal cell line it was called HEK-293.
Read more
Even though the descendants of foetal cells are used to produce the vaccine, the actual vaccination does not contain any foetal cells, or pieces of foetal DNA.
This cell line, and others like it, are commonly used in medical research. Indeed six of the COVID-19 vaccine candidates in development across the globe use human foetal cell lines.
Foetal cells derived from elective terminations of pregnancy have been commonly used in scientific research since the 1960s.
Their unique properties, such as an ability to be grown easily in the lab into cell lines, and the extensive knowledge about these cells gathered over decades of research, has seen them used to manufacture many vaccines, including those commonly used against rubella, chickenpox, hepatitis A, and shingles.
Again like in the production of the Oxford vaccine, there is no residual foetal cells or DNA in the actual vaccines.
Foetal cells have also been used to make approved drugs against diseases including haemophilia, rheumatoid arthritis, and cystic fibrosis and to study infectious diseases like Zika and HIV.
Read more
It is important to clarify that while foetal cells are sometimes referred to as embryonic cell lines, this should not be confused with the use of human embryos or creation of embryonic stem cells.
Foetal cells are obtained from donated tissue following termination of pregnancy or spontaneous miscarriage, while embryonic stem cells are obtained from donated human embryos originally created in the course of infertility treatment at an IVF clinic.
The term embryonic can refer to a stage of development both before and after a pregnancy is established.
HEK-293 cell line may be correctly described as being from embryonic kidney cells but is quite different to the use of human embryos to make an embryonic stem cell line that could be used in research to understand kidney disease or how kidneys develop.
The use of human embryos in research is highly regulated in Australia and elsewhere across the globe. While advances in stem cell research have reduced the need for foetal cells in certain areas of research, there remains a clear need for foetal tissue research.
The letter to the Prime Minister cites concerns that using products from the HEK-293 line amounts to benefiting from an elective termination, and therefore makes one complicit in a moral wrong.
Read more
This is only a concern for people who believe terminating a pregnancy is a moral wrong. This position would have far-ranging implications for public health, beyond the use of the Oxford vaccine.
Many currently available vaccines, and some other COVID-19 vaccine candidates, are produced using foetal cell lines.
More fundamentally the use of foetal cells lines is a ubiquitous part of medical research, leading to many techniques and drugs that are commonly used in medicine and have contributed to advances that have saved many lives.
Even those who have no moral objection to elective termination of pregnancy may have other concerns about the use of human or animal cell lines.
Ethical standards have improved greatly in the last few decades, and we need to confront some ethically suspect practices of the past. But one way we should respond to past bad practices is to learn from them and improve our standards.
In Australia, research using foetal tissue is subject to careful oversight under the National Statement on Ethical Conduct in Human Research (National Statement), which exemplifies the values of respect, research merit and integrity, justice, and beneficence.
Read more
The National Statement acknowledges that human research carries a potential risk of harm, discomfort and/or inconvenience for participants and/or others and therefore requires that the potential benefits of the research justify any risks involved.
It also requires that those who conscientiously object to being involved in conducting research with foetal tissue are not compelled to participate or put at a disadvantage because of their objection. This concession reflects the value of respect for human life and the beliefs of those involved in research.
While one of the letters authors, Sydneys Archbishop Anthony Fisher, has subsequently stressed that he does not think that it would be unethical to use this vaccine if there is no alternative available, and that he wont be critical of anyone who uses the vaccine.
His call for ethically untainted alternative might be difficult to meet given the long and deep role that foetal tissue has played in medical research.
Its unlikely that any COVID-19 vaccine will be entirely free from the use foetal cell lines, as some knowledge gained from those cell lines will go into any vaccine that is created.
Read more
While this issue may not be easily resolved, it is important to continue discussing ethical issues as we race to develop safe and effective treatments and/or vaccines for COVID-19.
As acknowledged in the National Statement, the risks and benefits of human research must always be considered to promote ethically good research.
The development of a safe and effective vaccine for COVID-19 carries significant benefit for the community, thereby promoting the values of research merit and integrity and beneficence.
Another core value in the National Statement is justice, which includes procedural justice (fair treatment in the recruitment of participants and the review of research) and distributive justice (fair distribution of the benefits and burdens of research).
As new vaccines are developed, it will therefore be important to uphold rigorous ethical standards in both laboratory and clinical research and ensure equitable distribution of the vaccine on a global scale.
Banner: Getty Images
Read the original:
Gaining clarity on the ethical issues of a possible COVID-19 vaccine - Pursuit
- Organoids and the future of medicine: from discovery to patient impact - Nature - April 15th, 2025
- Tracking Tissue Development to Inspire Regenerative Therapies - the-scientist.com - April 11th, 2025
- Space Doctors and Stem Cell Production in Microgravity - Cedars-Sinai - April 11th, 2025
- Study aims to stop Alzheimers with stem cell infusions - Drug Target Review - April 11th, 2025
- Why Menstrual Blood May Be 'Goldmine' for Personalized Medicine From Endometriosis to Diabetes and Cancer - Study Finds - April 11th, 2025
- Key Trends Shaping the Future of Stem Cell Assay Market:Innovative Product For Stem Cell Development - WhaTech - April 11th, 2025
- First of its kind stem cell transplant treatment in Boston restores vision to patient - Yahoo - April 8th, 2025
- People are getting costly stem cell injections for knee osteoarthritis, but we don't know if they work - Medical Xpress - April 6th, 2025
- Say goodbye to joint pain without surgery: Expert shares 8 tips on diet plan, lifestyle tweaks, treatments and therapies - Hindustan Times - April 6th, 2025
- Breaking Barriers in Autism: European Wellness Biomedical Group Unveils Bioregenerative Breakthroughs with Prof. Mike Chan -... - April 6th, 2025
- Revolutionizing Success in the Cell Therapy Regenerative - openPR.com - April 4th, 2025
- 5 Best Stem Cell Companies to Invest In (April 2025) - Securities.io - April 4th, 2025
- Boys with cancer can face infertility as adults. Can storing their stem cells help? - Ravalli Republic - April 4th, 2025
- Tip Sheet: Nutrition for People Receiving Stem Cell Transplants, Art Therapy for Cancer Patients, Treating a Rare Type of Colon Cancer and Graduate... - April 4th, 2025
- Human Organoid Market is Set to Revolutionize Drug Discovery and Disease Modeling - openPR.com - April 1st, 2025
- Doctors Told Him He Was Going to Die. Then A.I. Saved His Life. - The New York Times - March 24th, 2025
- Japan team says stem cell treatment helped improve spinal cord injuries | NHK WORLD-JAPAN News - NHK WORLD - March 22nd, 2025
- Boost in cancer treatment: PGI working on lab for stem cell, gene therapies - The Times of India - March 19th, 2025
- Stem Cell Stocks on the Rise: Companies Driving the $48 Billion Market Boom - openPR - March 19th, 2025
- Neuroregeneration Therapy Market Forecasted to Expand at 5.3% CAGR, Reaching USD 64.8 Billion by 2034 - Transparency Market Research, Inc -... - March 19th, 2025
- Cell Therapy Market Surges as Breakthrough Innovations Transform Regenerative Medicine - openPR - March 17th, 2025
- Infinite Health Integrative Medicine Center Fights Chronic Pain with Stem Cell Prolotherapy - PR Newswire - March 14th, 2025
- Stem Cell and Exosome Innovations at Infinite Health Integrative Medicine Center Offers New Hope for Parkinson's Disease - PR Newswire - March 14th, 2025
- Adia Nutrition Hunts for Top Sales Talent to Power Adia Med and Adia Labs Expansion - TradingView - March 14th, 2025
- Cell Therapy Market Poised for Exponential Growth, Projected to Reach USD 44.6 Billion by 2034 - openPR - March 14th, 2025
- Trial Repairs Irreversible Corneal Damage With Stem Cell Therapy - Anti Aging News - March 11th, 2025
- Advancing Regenerative Medicine: A Comprehensive Outlook on the Global Cell Therapy Market - openPR - March 7th, 2025
- Top 3 Grants in Regenerative Medicine: February 2025 - RegMedNet - March 7th, 2025
- The future of cell therapy: scaling production for global reach - Drug Target Review - March 7th, 2025
- Stem Cell Therapy Repairs Corneal Damage in Trial - Mirage News - March 7th, 2025
- Autologous Cell Therapy Market Anticipated to Hit USD 12.1 Billion by 2031: Persistence Market Research Study - openPR - March 7th, 2025
- Regenerative Therapies Market Forecast to Reach USD 24.41 Billion by 2033 - Persistence Market Research - openPR - March 5th, 2025
- This Japanese Regenerative Medicine Company Just Secured Its Path to NASDAQ Through a $242M Deal - StockTitan - March 5th, 2025
- Ryoncil, the first FDA-approved mesenchymal stromal cell therapy - Yahoo - March 5th, 2025
- Animal Stem Cell Therapy Market Forecast to Reach USD 437.3 - openPR - March 3rd, 2025
- A Navy SEALs Journey to Stem Cell Treatment: The Future of Medicine is Here, Just Not in America - SOFREP - March 3rd, 2025
- InnovationRx: Eli Lilly Has Stockpiled Nearly $550 Million Of Its Next Obesity Drug - Forbes - March 3rd, 2025
- VUMC Part of New Study Validating Curative Therapy for Sickle Cell Disease A - Wgnsradio - March 1st, 2025
- Advancing Stem Cell Therapy and Equity in Patient Care - Targeted Oncology - February 27th, 2025
- How Stem Cell Treatment Reversed A Pro Athlete's Life-threatening Long COVID Disease When all Other treatment Failed - Medical Tourism Magazine - February 27th, 2025
- Allogeneic Cell Therapy Market Size to Hit USD 4,677.38 Million by 203 - BioSpace - February 27th, 2025
- Bringing Fibroblasts to the Spotlight: Q&A with FibroBiologics - Pharmaceutical Executive - February 27th, 2025
- Mount Sinai-Led Research Team Identifies Underlying Mechanisms of Age-Related Dysfunction in Glands Crucial to Eye Function | Newswise - Newswise - February 25th, 2025
- Experts explore the future of iPSC-based cell therapies - Drug Target Review - February 19th, 2025
- Longeveron Announces World Health Organization Approval of laromestrocel as International Non-proprietary Name for Stem Cell Therapy Lomecel-B -... - February 19th, 2025
- The impact of cytokines on stem cells and organoid research in drug discovery - News-Medical.Net - February 19th, 2025
- Revolutionary FDA-Approved Stem Cell Partnership Puts Adia Med at Forefront of Regenerative Medicine - StockTitan - February 19th, 2025
- Bahrain Makes History with First Successful CRISPR-Based Sickle Cell Treatment Outside the US - BioSpace - February 19th, 2025
- Bahrain's pioneering use of sickle cell disease treatment hailed by medical experts - The National - February 19th, 2025
- Uganda Treats First Patient Using Stem Cell Therapy - AllAfrica - Top Africa News - February 19th, 2025
- Bahrain Makes History with First Successful CRISPR-Based Sickle Cell Treatment Outside the US - StreetInsider.com - February 17th, 2025
- Diversity of Cells Allow Colon Cancer to Resist Treatment and To Metastasize - MedicalResearch.com - February 15th, 2025
- Survival outcomes between haploidentical stem cell transplantation and chemotherapy for blastic plasmacytoid dendritic cell neoplasm - Nature.com - February 13th, 2025
- Experimental cell therapy trial treats first Sjgrens disease patient - University of Wisconsin School of Medicine and Public Health - February 11th, 2025
- Stem Cell Therapy Market Types, Applications, Share, Growth - openPR - February 6th, 2025
- Placental Stem Cell Therapy Solution Market Size And Booming - openPR - February 6th, 2025
- Revitalizing Health with Stem Cell Therapy: A Groundbreaking Path To Longevity and Wellness - openPR - February 4th, 2025
- Gene therapy offers new hope for sickle cell disease patients - Open Access Government - February 4th, 2025
- Scientists trial implant to patch up the heart - BBC.com - February 2nd, 2025
- Cell Therapy Market Size is Projected to Reach USD 33.93 - GlobeNewswire - January 28th, 2025
- Meet the California Institute Pushing Stem Cell & Gene Therapy Research: Part 3 - The Medicine Maker - January 28th, 2025
- Immusoft to Present Positive Data from the First Engineered B Cell in a Human Clinical Trial at the 21st Annual WorldSymposium 2025 - The Eastern... - January 28th, 2025
- Beyond the Lab: Stem cell research - Drug Target Review - January 25th, 2025
- Asia Pacific Stem Cell Therapy Market to Reach US$ 4,075.75 Million by 2033 with a Robust CAGR of 10.29% - openPR - January 25th, 2025
- Exciting data: S.Biomedics preps US IND of PD cell therapy - BioWorld Online - January 25th, 2025
- $24.85 Billion Cell Therapy Market Forecast by 2032 (CAGR 20.4%) - openPR - January 25th, 2025
- Stem Cell Therapy Market Expected to Expand at a Steady 2025-2032 - openPR - January 25th, 2025
- Regenerative Medicine Market to receive overwhelming hike US$ 164.9 billion in Revenues by 2032, Growing at a CAGR of 23.30% From 2024 to 2032 -... - January 25th, 2025
- Alternative medicine fans see RFK Jr. as a hero. The fields skeptics worry. - The Washington Post - January 23rd, 2025
- U.S. PRP and Stem Cell Alopecia Treatment Market Analysis 2025-2030 by Treatment, Indication, and End-use - Androgenic Alopecia Dominated the Market... - January 23rd, 2025
- The Future of Regenerative Medicine Lies in the Hands of Chiropractors - Dynamic Chiropractic - January 23rd, 2025
- Stem Cell Therapy Industry Dynamics and Contributions by RTI - openPR - January 21st, 2025
- Stem Cells Market to Reach USD 44.27 Billion by 2033, Driven by Expanding Applications and Innovations - openPR - January 21st, 2025
- Organoids at the Forefront Innovations in Stem Cell Research and Precision Medicine - openPR - January 21st, 2025
- The promising future of regenerative medicine - Yahoo Finance - January 17th, 2025
- An earful of gill: USC Stem Cell study points to the evolutionary origin of the mammalian outer ear - EurekAlert - January 11th, 2025
- Aspen Partners with Mytos to Automate Stem Cell Production for Parkinsons Therapy - Genetic Engineering & Biotechnology News - January 9th, 2025
- School of Medicine professor receives grant to study improved cancer treatments - Mercer University - January 9th, 2025
- Meet CIRM: the California Institute Pushing Stem Cell and Gene Therapy Research: Part 1 - The Medicine Maker - January 7th, 2025
- Regenerative Medicine Market to Experience Significant Growth, Projected to Reach $183.08 Billion by 2031. - openPR - January 7th, 2025
Recent Comments